Hearing On Neurontin Injunction Closes Without Ruling
Attorneys for Pfizer had hoped to persuade Judge John C. Lifland of the U.S. District Court for the District of New Jersey to bar generics maker Alpharma from launching a generic version of the $3 billion drug.
Analysts who have been observing the case aren’t optimistic about Pfizer’s chances.
"Based on the six hours of arguments we listened to yesterday, we are unswayed...
To view the full article, register now.